BioSpace News Archive

Deals

BioCryst Pharmaceuticals Commences Public Offering of $50 Million of Its Common Stock

BioCryst Pharmaceuticals, Inc. announced that it is offering to sell $50 million of its common stock in an underwritten public offering.

August 3, 2018
·
3 min read
Business

PRA Health Sciences, Inc. Reports Second Quarter 2018 Results and Updates Full Year 2018 Guidance

Net new business of $670.0 million; Net book-to-bill of 1.30

August 3, 2018
·
28 min read
Policy

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MabVax, Farmland, and ACADIA, and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of MabVax Therapeutics Holdings, Inc., Farmland Partners Inc., and ACADIA Pharmaceuticals Inc.

August 3, 2018
·
2 min read
Deals

BioCryst Pharmaceuticals Prices Public Offering of 9,090,910 Shares of Its Common Stock

BioCryst Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock, offered at a price to the public of $5.50 per share.

August 3, 2018
·
3 min read
Deals

Breathtec to Open New Drug Development Division, Signs LOI to acquire 100% of Clinical Stage Nash Pharmaceuticals Inc.

Breathtec Biomedical Inc. is pleased to announce that it will be opening a new drug development division and has signed a Letter of Intent (“LOI”) to acquire 100% of the shares of Nash Pharmaceuticals Inc.

August 3, 2018
·
7 min read
Pharm Country

Transforming the Service Experience Helps Konica Minolta Healthcare Maintain its Leadership in Customer Satisfaction

At Konica Minolta Healthcare Americas, Inc., a customer-centric approach is evident by the company’s consistent top ratings from MD Buyline for its exceptional digital radiography platform and customer service.

August 3, 2018
·
3 min read
Drug Development

Tempus to Participate in the NCI-MATCH Clinical Trial

Having met rigorous qualifications, Tempus joins a select group of commercial and academic laboratories designated to cast a wider net for patients to enter the trial

August 3, 2018
·
3 min read
Business

Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update

Second Quarter Conference Call and Webcast Scheduled Today at 4:30 PM ET

August 3, 2018
·
15 min read
IMPACT Therapeutics Raises $30 Million In Series C Financing

IMPACT Therapeutics, Inc. (IMPACT) today announced the completion of $30 million in series C financing.

August 3, 2018
·
3 min read
Business

Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

Innovus Pharmaceuticals, Inc. announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S. financial markets.

August 3, 2018
·
3 min read